

Bod signs agreement with Australia's largest pharmacy wholesaler, Symbion

- Symbion is the largest Australian pharmacy wholesaler servicing over 3,500 customers across
 Australia clients include Good Price, Terry White, Chemmart and Pharmacy for Less
- Bod's entire natural medicines range as well as leading pregnancy supplement range, Mamacare to be stocked with the wholesaler
- This follows on from Bod's agreement API with the Company now having access to over two thirds of the Pharmacy market through agreements with two of Australia's leading pharmacy wholesalers
- Products to be live in coming weeks sales expected in near term
- Agreement allows for Bod to build greater market positioning, improved working capital management and centralised deliveries

Sydney, Australia – 9 April 2018: Developer and distributor of natural, evidence-based cosmetics, natural medicines and health products, Bod Australia Limited ("Bod" or the "Company") (ASX: BDA) is pleased to advise that it has secured an agreement with one of Australia's leading pharmaceutical wholesalers, Symbion. Under the agreement, Symbion will now stock Bod's entire range of natural medicines, as well as pregnancy supplement and skincare range, Mamacare.

Symbion is Australia's largest pharmacy wholesalers, owned by the listed company Ebos Group Ltd (Market Capitalisation \$2.6B), it provides products and services to over 3,500 pharmacy customers across the nation. The business boasts 10 warehouses located across the country and coordinate daily deliveries to pharmacies through longstanding relationships with delivery partners.

Similar to the Company's agreement with API (refer ASX announcement: 5 April 2018), this allows Bod to better utilise working capital by leveraging centralised delivery points and more stringent payment periods. It also allows Symbion's 3,500 strong retailer customer base simplified and convenient access to the Company's products ensuring Bod's products achieve greater market shares across pharmacies and specialty retailers.

Board and Management expect all ranges and associated stock keeping units (SKU's) to be live in Symbion's system in the coming weeks and will work in conjunction with the wholesaler to ensure its products are promoted adamantly.

Bod Australia CEO Jo Patterson said: "We are excited to have our natural medicines range and Mamacare pregnancy supplement stocked with another one of Australia's leading pharmacy wholesalers.

"Not only does this agreement provide ongoing validation of our product range, but coupled with the recent progression of our relationship with API, it provides the Company with access to over two thirds of the Australian pharmaceutical market.

"We look forward to working with Symbion to promote our products through their network of over 3,500 pharmacies and specialty retailers to ensure Bod's products achieve greater market penetration and drive revenue growth.

"We are continually pursuing opportunities to increase our distribution footprint and look forward to updating shareholders as these developments materialise."

For more information: bodaustralia.com



- ENDS -

About Bod Australia

Bod Australia Limited operates two integrated business units. The Company is a developer and distributor of cosmetics and natural medicines, focused on all natural, evidence based products. Bod has developed a significant distribution footprint in the Australian market with access to over 800 pharmacies and is also targeting Asian markets through key daigou relationships. Bod Australia is also building a sustainable, multifaceted cannabis business through a supply and collaboration agreement with Swiss botanical extracts manufacturer, Linnea Natural Pharma Solutions. The Company aims to develop a range of over the counter and therapeutic products based on GMP-certified cannabis extracts.

For more information please contact:

Jo Patterson Bod Australia +61 2 9199 5018

Henry Jordan – Six Degrees Investor Relations Henry.jordan@sdir.com.au +61 431 271 538